Arteries, Anomalies of

Categories: Cardiovascular diseases

Aliases & Classifications for Arteries, Anomalies of

MalaCards integrated aliases for Arteries, Anomalies of:

Name: Arteries, Anomalies of 56
Artery Disease 12 15
Arteriopathic Disease 71



autosomal dominant


arteries, anomalies of:
Inheritance autosomal dominant inheritance


External Ids:

Disease Ontology 12 DOID:0050828
OMIM 56 108000
MedGen 41 C1876179
SNOMED-CT via HPO 68 263681008 49601007
UMLS 71 C0852949

Summaries for Arteries, Anomalies of

Disease Ontology : 12 A vascular disease that is located in an artery.

MalaCards based summary : Arteries, Anomalies of, also known as artery disease, is related to carotid artery disease and cerebral arterial disease. An important gene associated with Arteries, Anomalies of is MIR199A1 (MicroRNA 199a-1), and among its related pathways/superpathways are MicroRNAs in cancer and Peptide hormone metabolism. The drugs Coal tar and Nicardipine have been mentioned in the context of this disorder. Affiliated tissues include an artery, heart and endothelial, and related phenotype is abnormality of the cardiovascular system.

More information from OMIM: 108000

Related Diseases for Arteries, Anomalies of

Diseases related to Arteries, Anomalies of via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1186)
# Related Disease Score Top Affiliating Genes
1 carotid artery disease 35.3 REN MIR126 CRP ACE
2 cerebral arterial disease 34.8 SERPINA3 MIR145 MIR126
3 renal artery disease 34.8 REN CRP ACE
4 peripheral vascular disease 34.7 INS H2AC18 CRP ACE
5 coronary artery anomaly 34.6 MIR21 MIR199A1 MIR145 MIR126 CRP ACE
6 coronary heart disease 1 34.3 MIR17 MIR155 MIR145 MIR126 INS CRP
7 vascular disease 33.7 REN MIR21 MIR199A1 MIR146A MIR145 MIR126
8 angina pectoris 33.7 INS CRP ACE
9 arteriosclerosis 33.5 MIR21 MIR155 MIR126 INS CRP ACE
10 myocardial infarction 33.5 SERPINA3 REN MIR423 MIR210 MIR21 MIR17
11 cardiovascular system disease 33.3 SERPINA3 REN MIR590 MIR423 MIR24-1 MIR210
12 familial hypercholesterolemia 33.3 INS H2AC18 CRP ACE
13 heart disease 33.3 REN MIR423 MIR210 MIR21 MIR199A1 MIR155
14 aortic disease 33.2 REN MIR199A1 MIR145 CRP ACE
15 arteriosclerosis obliterans 33.2 MIR24-1 MIR21 MIR133A1
16 intermediate coronary syndrome 32.7 REN MIR126 INS CRP ACE
17 lipid metabolism disorder 32.6 MIR33A MIR126 INS H2AC18 CRP ACE
18 hypercholesterolemia, familial, 1 32.6 INS CRP ACE
19 cerebrovascular disease 32.4 SERPINA3 REN MIR21 MIR199A1 INS CRP
20 carotid stenosis 32.4 REN CRP ACE
21 congestive heart failure 32.3 REN INS CRP ACE
22 kidney disease 32.3 SERPINA3 REN MIR199A1 MIR17 MIR155 MIR126
23 acute myocardial infarction 32.2 REN MIR423 MIR21 MIR126 INS CRP
24 diabetes mellitus 32.2 REN MIR17 MIR155 MIR146A MIR145 MIR126
25 atrial fibrillation 32.1 REN MIR21 MIR199A1 MIR133A1 MIR126 INS
26 aortic aneurysm, familial abdominal, 1 32.1 MIR199A1 CRP ACE
27 heart valve disease 32.0 SERPINA3 REN MIR423 MIR21 MIR199A1 MIR146A
28 diabetes mellitus, noninsulin-dependent 32.0 SERPINA3 REN MIR423 MIR21 MIR199A1 MIR17
29 mitral valve insufficiency 32.0 REN MIR423 CRP ACE
30 sleep apnea 31.9 REN INS CRP ACE
31 pulmonary disease, chronic obstructive 31.9 SERPINA3 MIR423 MIR199A1 MIR126 INS H2AC18
32 non-alcoholic fatty liver disease 31.8 MIR33A MIR21 MIR17 MIR126 INS CRP
33 hypertension, essential 31.8 REN MIR590 MIR423 MIR33A MIR24-1 MIR210
34 aortic valve disease 2 31.8 SERPINA3 REN MIR423 MIR21 MIR199A1 MIR17
35 body mass index quantitative trait locus 11 31.7 SERPINA3 REN MIR423 MIR21 MIR199A1 MIR17
36 microvascular complications of diabetes 3 31.7 REN MIR21 INS ACE
37 systemic lupus erythematosus 31.7 MIR423 MIR210 MIR21 MIR155 MIR146A INS
38 generalized atherosclerosis 31.6 REN INS CRP ACE
39 peripheral nervous system disease 31.6 SERPINA3 MIR21 MIR126 INS H2AC18 CRP
40 mitral valve stenosis 31.6 SERPINA3 REN CRP ACE
41 microvascular complications of diabetes 5 31.6 MIR21 MIR126 INS H2AC18 ACE
42 aortic valve insufficiency 31.5 REN CRP ACE
43 mitral valve disease 31.5 REN MIR423 CRP ACE
44 hyperuricemia 31.5 REN INS CRP
45 mental depression 31.5 SERPINA3 MIR24-1 H2AC18 CRP
46 pulmonary hypertension 31.5 REN MIR21 MIR17 CRP ACE
47 heart septal defect 31.4 MIR423 MIR199A1 H2AC18
48 rheumatic disease 31.4 MIR155 MIR146A H2AC18 CRP CCR6
49 pulmonary edema 31.4 REN CRP ACE
50 familial hyperlipidemia 31.4 INS H2AC18 CRP ACE

Graphical network of the top 20 diseases related to Arteries, Anomalies of:

Diseases related to Arteries, Anomalies of

Symptoms & Phenotypes for Arteries, Anomalies of

Human phenotypes related to Arteries, Anomalies of:

# Description HPO Frequency HPO Source Accession
1 abnormality of the cardiovascular system 31 HP:0001626

Symptoms via clinical synopsis from OMIM:

abnormal radial, ulnar, or interosseous artery

Clinical features from OMIM:


Drugs & Therapeutics for Arteries, Anomalies of

Drugs for Arteries, Anomalies of (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 857)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Coal tar Approved Phase 4 8007-45-2
Nicardipine Approved, Investigational Phase 4 55985-32-5 4474
Esmolol Approved Phase 4 81147-92-4, 103598-03-4 59768
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
Fenoldopam Approved Phase 4 67227-56-9, 67227-57-0 3341
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
9 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
Udenafil Approved, Investigational Phase 4 268203-93-6 6918523
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
Salicylic acid Approved, Investigational, Vet_approved Phase 4 69-72-7 338
Eplerenone Approved Phase 4 107724-20-9 150310 443872
Dobutamine Approved Phase 4 34368-04-2 36811
Ticlopidine Approved Phase 4 55142-85-3 5472
Simvastatin Approved Phase 4 79902-63-9 54454
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
Pravastatin Approved Phase 4 81093-37-0 54687
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
Probucol Approved, Investigational Phase 4 23288-49-5 4912
Ramipril Approved Phase 4 87333-19-5 5362129
Glipizide Approved, Investigational Phase 4 29094-61-9 3478
Remifentanil Approved Phase 4 132875-61-7 60815
Abciximab Approved Phase 4 143653-53-6
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
Lovastatin Approved, Investigational Phase 4 75330-75-5 53232
Saxagliptin Approved Phase 4 361442-04-8 11243969
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
Digoxin Approved Phase 4 20830-75-5 30322 2724385
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
Repaglinide Approved, Investigational Phase 4 135062-02-1 65981
Histamine Approved, Investigational Phase 4 51-45-6 774
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
Citalopram Approved Phase 4 59729-33-8 2771
Magnesium citrate Approved Phase 4 3344-18-1
Magnesium oxide Approved Phase 4 1309-48-4 14792
Cosyntropin Approved Phase 4 16960-16-0 16129617
Etomidate Approved Phase 4 33125-97-2 36339 667484
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
Nifedipine Approved Phase 4 21829-25-4 4485
Methylnaltrexone Approved Phase 4 916055-93-1, 83387-25-1 6603824
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
Linagliptin Approved Phase 4 668270-12-0 10096344

Interventional clinical trials:

(show top 50) (show all 5800)
# Name Status NCT ID Phase Drugs
1 Comparison of Biolimus-eluting Biodegradable Polymer, Everolimus-eluting and Sirolimus-eluting Coronary Stents Unknown status NCT01268371 Phase 4
2 A Multi Center Registry to Evaluate Multiple Stenting Using by Everolimus-eluting Stents for Treatment of Long Coronary Artery Disease Unknown status NCT01147237 Phase 4
3 Clinical Evaluation of the Momo Cobalt-Chromium Coronary Stent System for the Treatment of Patients With Coronary Artery Disease Unknown status NCT01535625 Phase 4
4 Randomized Controlled Clinical Study to Compare the Efficacy and Safety of Different Dose of Tirofiban in Interventional Treatment of Complex Coronary Artery Disease Unknown status NCT02294994 Phase 4 tirofiban
5 Comparison of Efficacy and Safety of Ivabradine Versus Metoprolol for Controlling Heart Rate Prior to 640-Slice Computed Tomographic Angiography in Elective Patients Unknown status NCT01755663 Phase 4 Ivabradine and Metoprolol
6 Simultaneous Acquisition of Intravascular Ultrasound and Near Infrared Spectroscopy Data in the Coronary Artery Study Unknown status NCT02154295 Phase 4
7 Ranolazine, Ethnicity and the Metabolic Syndrome - REMS Study Unknown status NCT01304095 Phase 4 Ranolazine
8 The Effects of Omega 3 and Vitamin E Supplementation on the Serum Antioxidant Enzymes and Gene Expressions of PGC-1a, h TERT, FOXOs and SIRTs in CAD Patients Unknown status NCT02011906 Phase 4
9 Graft Patency After FFR-guided Versus Angio-guided CABG: a Prospective, Multicenter, Multinational, Randomized (1:1) Controlled Trial Unknown status NCT01810224 Phase 4
10 Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy Unknown status NCT01869309 Phase 4 Prasugrel;Ticagrelor
11 Prospective Multicenter Registry of Hybrid Coronary Artery Revascularization Combined With Surgical Bypass and Percutaneous Coronary Intervention Using Everolimus Eluting Metallic Stents Unknown status NCT02894255 Phase 4
12 Low Dose Statins, Ezetimibe and Nutraceuticals in Coronary Artery Disease Patients Intolerant to High Intensity Statin Treatment (TArget ChOlesterol) Unknown status NCT03277079 Phase 4 statin + ezetimibe;statin + ezetimibe + Nutraceuticals
13 Effect of Preoperative Aspirin in Patients Undergoing Off-pump Coronary Artery Bypass Grafting: A Double-blind, Placebo-controlled, Randomized Trial Unknown status NCT03049085 Phase 4 Aspirin;vitamin C
14 Rosiglitazone Therapy In The Prevention Of Coronary Artery Disease In Patients With Impaired Glucose Tolerance Unknown status NCT00733174 Phase 4 Rosiglitazone;Placebo
15 A Randomized, Double-blind, Multi-centered, Placebo-controlled Trial to Examine Effects of Heart-protecting Musk Pill on Clinical Outcome in Patients With Chronic Stable Coronary Artery Disease Unknown status NCT01897805 Phase 4 Heart-protecting Musk Pill;Placebo
16 Hydroxychloroquine Assessment of Management Study in Coronary Artery Disease After Angiography. Unknown status NCT02874287 Phase 4 Hydroxychloroquine Sulfate Tablets;Placebo Tablets
17 Study of Curative Effect Evaluation of Shexiang Baoxin Pill on Coronary Artery Disease Not Amenable to Revascularization on the Basis of Western Medicine Therapy Unknown status NCT03072121 Phase 4 Shexiang Baoxin pill;SBP placebo;Aspirin Enteric-coated Tablets;Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet;Atorvastatin Calcium;Isosorbide Mononitrate Tab 20 MG;Metoprolol Tartrate Tab 25 MG;Trimetazidine Dihydrochloride Tablets
18 Study of Curative Effect Evaluation of DanLou Tablet on Coronary Artery Disease Not Amenable to Revascularization on the Basis of Western Medicine Therapy Unknown status NCT03072082 Phase 4 Danlou Tablet;DanLou Tablet placebo;Aspirin Enteric-coated Tablets;Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet;Atorvastatin calcium;Isosorbide Mononitrate Tab 20 MG;Metoprolol Tartrate Tab 25 MG;Trimetazidine Dihydrochloride Tablets
19 Diagnostic Value of a Rapid Protocol Regadenoson Stress Cardiovascular Magnetic Resonance Scan for Detection of Coronary Artery Disease Unknown status NCT01446094 Phase 4 regadenoson
20 A Prospective Multicenter Trial Evaluating Helios Biodegradable Polymer Sirolimus-eluting Stent Safety and Effectiveness in Treatment of Coronary Artery Disease Unknown status NCT01880879 Phase 4
21 The Beneficial Role of Percutaneous Coronary Intervention Over Optimal Medical Therapy in Elderly Patients (Age > 75 Years Old) With Coronary Artery Disease: a Randomized Controlled Study Unknown status NCT01508663 Phase 4 ARB, CCB, ACE-inhibitor, statin, Nitrate, Antiplate etc.
22 Randomized Trial of the Association Between Low-Dose Statins and Nutraceuticals in High-intEnsity Statin-intoleRant patiENts With Very High Risk Coronary Artery diseasE Unknown status NCT02001883 Phase 4 Association low-dose statin and nutraceuticals
23 Phase 4 Study of Patients Receiving BNP or NTG (IV) During Angioplasty, Re-examined 24 Hours Later Using the Flow-mediated Brachial Artery Dilation Study, and Blood Assays for Pro BNP and ET1 Unknown status NCT00262574 Phase 4 Nesiritide,
24 Apposition Assessed Using Optical Coherence Tomography of Chromium Stents Eluting Everolimus From Cobalt Versus Platinum Alloy Platforms. Unknown status NCT01776567 Phase 4
25 A Comparative Evaluation of Efficacy and Safety in the 3-Months DAPT Group vs. the 6-Months DAPT Group of Patients Treated With the Coroflex ISAR Stent; A Prospective, Multicenter, Randomized, Open-Label Clinical Trial Unknown status NCT02609698 Phase 4 3 months DAPT;6 months DAPT
26 Comparison of the Pharmacodynamic Effects of RanOlazine Versus aMlodipine on Platelet Reactivity in Stable Patients With Coronary Artery Disease Treated With Dual ANtiplatelet Therapy - The ROMAN Randomized Study Unknown status NCT01490255 Phase 4 Ranolazine;Amlodipine
27 Efficacy and Safety of the YUKON Drug Eluting Stent in Diffuse Coronary Artery Disease Unknown status NCT01418794 Phase 4
28 The 001-DIOR Multicenter Registry (A Novel Percutaneous Coronary Intervention With the New Paclitaxel-eluting Balloon DIOR in Ostial Bifurcated Lesions) Unknown status NCT01375465 Phase 4
29 Impact of Paclitaxel-eluting Stent for Small Coronary Artery Disease Unknown status NCT00955214 Phase 4
30 Randomized Placebo-controlled Crossover Trial of Endothelial Function Improvement in Subjects With History of Premature Coronary Artery Disease Unknown status NCT00917527 Phase 4 Atorvastatin
31 Multicenter, Randomized, Non-inferiority Study of Firebird 2 Versus Excel Sirolimus-eluting Stent in Treating Real-world Patients With Coronary Artery Disease Unknown status NCT01373632 Phase 4
32 Individual-Patient-Data Pooled-Analysis of Diagnostic Accuracy of Noninvasive Fractional Flow Reserve From Anatomic CT Angiography Unknown status NCT01747317 Phase 4
33 Multivessel Stenting and Staged Revascularization for ST-elevation Myocardial Infarction Patients With Resolute Integrity Stents Unknown status NCT01781715 Phase 4
34 Pharmacodynamic Effects of Atorvastatin vs. Rosuvastatin on pLatelet Reactivity in Stable Patients With Coronary Artery Disease Treated With Dual Antiplatelet Therapy Unknown status NCT01567774 Phase 4 Atorvastatin;Rosuvastatin
35 Cilostazol Enhances the Number and Functions of Circulating Endothelial Progenitor Cells and Endothelial Function Mediated Through Modification of Vasculogenesis and Angiogenesis Factors in Patients With Stable Coronary Artery Disease Unknown status NCT02174939 Phase 4 Cilostazol;Dummy Placebo
36 Use of Hypertonic Versus Isotonic Solutions in Off Pump Coronary Artery Bypass Graft Surgery Targeting the Left Marginal Branch Unknown status NCT01463917 Phase 4 Hypertonic solution;Isotonic
37 Comparison of Hyperemic Efficacy Between Nicorandil and Adenosine for Fractional Flow Reserve (FFR) Measurement Unknown status NCT01331902 Phase 4
38 A Pilot Study Exploring Efficacy and Safety of Amlodipine in the Stented Angina Patients Unknown status NCT01120327 Phase 4 Placebo;Amlodipine
39 Prospective Randomized Study of the Paclitaxel-Coated Balloon Catheter in Bifurcated Coronary Lesions / BABILON Study (Paclitaxel-Coated Balloon in Bifurcated Lesions) Unknown status NCT01278186 Phase 4
40 Comparison of Vascular Remodeling Between Different Antianginal Medication Evaluated by Noninvasive ECG-gated Fundus Photographic Evaluation Unknown status NCT01162902 Phase 4 Diltiazem treated group;Bisoprolol treated group;Candesartan treated group
41 2-phased Randomized Comparison Between PromusTMElementTM Versus Xience PRIME® Stent Unknown status NCT01581515 Phase 4
42 Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention Unknown status NCT02334254 Phase 4 rivaroxaban and ticagrel therapy;triple antithrombotic regimen with warfarin, asipirin and clopidogrel
43 Assessment of Surface Coverage of Polymer-based Sirolimus-eluting Stent( Cypher ) or Polymer-free Paclitaxel-eluting Stent (YinYi )in Diabetes Mellitus and Non- Diabetes Mellitus Patients by Optical Coherence Tomography Unknown status NCT01023919 Phase 4
44 Randomized Comparison of the CHOlesterol-lowering Effects of nutraceuticaLs Versus Ezetimibe in Statin-intolerant patientS - The CHOLESS Trial Unknown status NCT01807078 Phase 4 Ezetimibe
45 Prospective Randomized Trial On Radiation Dose Estimates Of CT Angiography In Patients Applying Iterative Image Reconstruction Techniques - The PROTECTION V Study - Unknown status NCT01453712 Phase 4
46 The Efficacy and Safety of Paclitaxel-eluting SeQuent Please Drug-Eluting Balloon for Treatment of lesiOns in Native smalL coronarY Arteries (DEB-ONLY) Unknown status NCT01903902 Phase 4
47 The Impact of Rosuvastatin on the Density Score of Coronary Artery Calcification in CAD Patients With Diabetes Mellitus Unknown status NCT02418884 Phase 4 rosuvastatin
48 Relationship Between Initial Plaque Characteristics and Stent Surface Coverage Patterns After Sirolimus-eluting Stent Implantation Assessment by Optical Coherence Tomography Unknown status NCT01024179 Phase 4
49 Assessment of the Effects of Ezetimibe on Coronary Plaque Volume in Patients With Acute Coronary Syndrome Unknown status NCT01068093 Phase 4 Ezetimibe
50 Same Lipid Lowering by Atorvastatin Versus Atorvastatin Plus Ezetimibe on Coronary Plaque Progression Unknown status NCT01086020 Phase 4 atorvastatin;atorvastatin plus ezetimibe

Search NIH Clinical Center for Arteries, Anomalies of

Genetic Tests for Arteries, Anomalies of

Anatomical Context for Arteries, Anomalies of

The Foundational Model of Anatomy Ontology organs/tissues related to Arteries, Anomalies of:

An Artery

MalaCards organs/tissues related to Arteries, Anomalies of:

Heart, Endothelial, Testes, Kidney, Bone, Liver, Lung

Publications for Arteries, Anomalies of

Articles related to Arteries, Anomalies of:

(show top 50) (show all 30005)
# Title Authors PMID Year
Serum osteoprotegerin level is positively associated with peripheral artery disease in patients with peritoneal dialysis. 61
31950864 2020
Homocysteine is an independent predictor of long-term cardiac mortality in patients with stable coronary artery disease in the era of statins. 61
31609754 2020
Long-term outcomes after percutaneous coronary intervention relative to bypass surgery in diabetic patients with multivessel coronary artery disease according to clinical presentation. 61
31219843 2020
Relationship between C-reactive protein-to-albumin ratio and the extent of coronary artery disease in patients with non-ST-elevated myocardial infarction. 61
31233399 2020
Effect of genetic liability to migraine on coronary artery disease and atrial fibrillation: a Mendelian randomization study. 61
31661179 2020
Upregulation of microRNA-218 reduces cardiac microvascular endothelial cells injury induced by coronary artery disease through the inhibition of HMGB1. 61
31566720 2020
The Impact of Peripheral Artery Disease in Chronic Total Occlusion Percutaneous Coronary Intervention (Insights From PROGRESS-CTO Registry). 61
31845593 2020
Silent coronary artery disease in asymptomatic patients with severe aortic stenosis and normal exercise testing. 61
31577622 2020
Is Admission Heart Rate an Optimal Predictor for Coronary Artery Disease Complexity? 61
31514511 2020
Trends in statin utilization among adults with severe peripheral artery disease including critical limb ischemia in an integrated healthcare delivery system. 61
31512991 2020
The power of myocardial blood flow reserve in personalizing management of patients with stable coronary artery disease. Is it time to move on from percentage of ischaemia? 61
31327015 2020
Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial. 61
31615291 2020
Financial barriers in accessing medical care for peripheral artery disease are associated with delay of presentation and adverse health status outcomes in the United States. 61
31603393 2020
Differential Prognostic Impact of Atrial Fibrillation in Hospitalized Heart Failure Patients With Preserved Ejection Fraction According to Coronary Artery Disease Status - Report From the Japanese Nationwide Multicenter Registry. 61
32009066 2020
Characteristics and in-hospital mortality of patients with myocardial infarction in the absence of obstructive coronary artery disease in super-aging society. 61
31740139 2020
Omega-3 supplement use, fish intake, and risk of non-fatal coronary artery disease and ischemic stroke in the Million Veteran Program. 61
30914216 2020
Adherence to Guideline-Recommended Therapy-Including Supervised Exercise Therapy Referral-Across Peripheral Artery Disease Specialty Clinics: Insights From the International PORTRAIT Registry. 61
31973609 2020
Comparison of Survival of Transfemoral Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement for Aortic Stenosis in Low-Risk Patients Without Coronary Artery Disease. 61
31831151 2020
A patient-centered multidisciplinary cardiac rehabilitation program improves glycemic control and functional outcome in coronary artery disease after percutaneous and surgical revascularization. 61
32037504 2020
Correction to: Real-World Predictors of Major Adverse Cardiovascular Events and Major Adverse Limb Events Among Patients with Chronic Coronary Artery Disease and/or Peripheral Arterial Disease. 61
31933050 2020
Diagnostic value of peak filling rate derived from ECG-gated myocardial perfusion SPECT for detecting myocardial ischaemia in patients with non-obstructive coronary artery disease. 61
30650017 2020
The intensity of oscillations of the photoplethysmographic waveform variability at frequencies 0.04-0.4 Hz is effective marker of hypertension and coronary artery disease in males. 61
31402715 2020
Low blood pressure and cardiovascular events in diabetic patients with coronary artery disease after revascularization: the CREDO-Kyoto registry cohort-1. 61
32015482 2020
Fasting Blood Glucose and HbA1c Correlate With Severity of Coronary Artery Disease in Elective PCI Patients With HbA1c 5.7% to 6.4. 61
31749367 2020
Chemokine (C-C motif) ligand 2 and coronary artery disease: Tissue expression of functional and atypical receptors. 61
31739217 2020
Depression in Nonhospitalized Jordanian Patients With Coronary Artery Disease. 61
31464796 2020
Vascular Disease Patient Information Page: Exercise for peripheral artery disease. 61
31830869 2020
Acute resveratrol supplementation in coronary artery disease: towards patient stratification. 61
31429599 2020
Hypocholesterolaemia and mortality in patients with coronary artery disease. 61
31863458 2020
Iron hypothesis and coronary artery disease in geriatric patients. 61
30032657 2020
Automated calcium scores collected during myocardial perfusion imaging improve identification of obstructive coronary artery disease. 61
31768415 2020
Impact of Lipoprotein(a) on Long-Term (Mean 6.2 Years) Outcomes in Patients With Three-Vessel Coronary Artery Disease. 61
31864520 2020
Impact of active smoking on the immature platelet fraction and its relationship with the extent of coronary artery disease. 61
31659742 2020
Hsa-miR-584-5p as a novel candidate biomarker in Turkish men with severe coronary artery disease. 61
31863331 2020
A genetic risk score predicts coronary artery disease in familial hypercholesterolaemia: enhancing the precision of risk assessment. 61
31571196 2020
Should Routine Screening for Coronary Artery Disease Be Recommended? A Comparison With Routine Screening for Colon Cancer. 61
31301292 2020
One-year results of drug-coated balloons for long and occlusive Femoropopliteal artery disease: a single-arm trial. 61
32028896 2020
Sub-segmental quantification of single (stress)-pass perfusion CMR improves the diagnostic accuracy for detection of obstructive coronary artery disease. 61
32028980 2020
Effects of heated water-based versus land-based exercise training on vascular function in individuals with peripheral artery disease. 61
32027542 2020
Relationship between body mass index and outcomes of coronary artery disease in Asian population: Insight from the FOCUS registry. 61
31685245 2020
Impact of diabetes mellitus on 5-year clinical outcomes following successful endovascular revascularization for peripheral artery disease. 61
31690244 2020
Retinal microvascular findings and risk of incident peripheral artery disease: An analysis from the Atherosclerosis Risk in Communities (ARIC) Study. 61
31812251 2020
When the Complex Meets the High-Risk: Mechanical Cardiac Support Devices and Percutaneous Coronary Interventions in Severe Coronary Artery Disease. 61
32036868 2020
Association of combined genetic variations in SOD3, GPX3, PON1, and GSTT1 with hypertension and severity of coronary artery disease. 61
32034489 2020
Circulatory miR-133b and miR-21 as Novel Biomarkers in Early Prediction and Diagnosis of Coronary Artery Disease. 61
32033332 2020
Does Creatine Supplementation Affect Renal Function in Patients with Peripheral Artery Disease? A Randomized, Double Blind, Placebo-controlled, Clinical Trial. 61
31563660 2020
13N-ammonia PET/CT stress myocardial blood flow compared to fractional flow reserve in coronary artery disease. 61
31764595 2020
Coronary artery calcium scoring in individuals at risk for coronary artery disease: current status and future perspectives. 61
31999209 2020
Correlation between adiponectin, chemerin, vascular endothelial growth factor and epicardial fat volume in patients with coronary artery disease. 61
32010275 2020
PET 18F-flurpridaz quantitative measurements of myocardial blood flow: Added value for diagnosis of coronary artery disease? Of course! 61
32020502 2020

Variations for Arteries, Anomalies of

Expression for Arteries, Anomalies of

Search GEO for disease gene expression data for Arteries, Anomalies of.

Pathways for Arteries, Anomalies of

GO Terms for Arteries, Anomalies of

Cellular components related to Arteries, Anomalies of according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.53 SERPINA3 REN MIR590 MIR423 MIR24-1 MIR210

Biological processes related to Arteries, Anomalies of according to GeneCards Suite gene sharing:

(show all 30)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.97 MIR21 MIR155 MIR146A MIR133A1 INS CRP
2 positive regulation of cell migration GO:0030335 9.92 MIR590 MIR210 MIR21 INS
3 positive regulation of protein kinase B signaling GO:0051897 9.88 MIR21 MIR199A1 MIR126 INS
4 positive regulation of angiogenesis GO:0045766 9.88 MIR210 MIR21 MIR199A1 MIR126
5 cellular response to hypoxia GO:0071456 9.85 MIR17 MIR155 MIR146A MIR126
6 negative regulation of gene expression GO:0010629 9.85 MIR33A MIR21 MIR17 MIR155 MIR146A ACE
7 negative regulation of inflammatory response GO:0050728 9.84 MIR590 MIR155 MIR146A MIR126
8 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.81 MIR21 MIR126 INS
9 positive regulation of inflammatory response GO:0050729 9.81 MIR21 MIR155 MIR126
10 negative regulation of angiogenesis GO:0016525 9.81 MIR24-1 MIR21 MIR146A MIR145
11 acute-phase response GO:0006953 9.73 SERPINA3 INS CRP
12 negative regulation of NIK/NF-kappaB signaling GO:1901223 9.7 MIR590 MIR21 MIR146A
13 miRNA mediated inhibition of translation GO:0035278 9.7 MIR590 MIR210 MIR21 MIR17 MIR155 MIR146A
14 positive regulation of connective tissue replacement GO:1905205 9.65 MIR199A1 MIR155
15 negative regulation of cardiac muscle hypertrophy GO:0010614 9.65 MIR21 MIR145 MIR133A1
16 positive regulation of reactive oxygen species biosynthetic process GO:1903428 9.64 MIR24-1 MIR155
17 cellular response to oxidised low-density lipoprotein particle stimulus GO:0140052 9.63 MIR155 MIR146A
18 negative regulation of reactive oxygen species biosynthetic process GO:1903427 9.63 MIR590 MIR21 INS
19 angiotensin maturation GO:0002003 9.62 REN ACE
20 negative regulation of blood vessel diameter GO:0097756 9.61 INS CRP
21 positive regulation of metalloendopeptidase activity GO:1904685 9.61 MIR21 MIR17
22 negative regulation of hydrogen peroxide-induced cell death GO:1903206 9.61 MIR17 MIR155 MIR133A1
23 negative regulation of regulatory T cell differentiation GO:0045590 9.6 MIR21 MIR155
24 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.59 MIR155 MIR146A
25 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.58 MIR199A1 MIR17 MIR155
26 positive regulation of cardiac muscle tissue regeneration GO:1905180 9.57 MIR590 MIR199A1
27 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.56 MIR199A1 MIR17 MIR155 MIR133A1
28 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.5 MIR210 MIR21 MIR17
29 gene silencing by miRNA GO:0035195 9.44 MIR590 MIR423 MIR33A MIR24-1 MIR210 MIR21
30 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.43 MIR590 MIR24-1 MIR21 MIR199A1 MIR145 MIR133A1

Molecular functions related to Arteries, Anomalies of according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.44 MIR590 MIR423 MIR33A MIR24-1 MIR210 MIR21
2 RNA polymerase II complex binding GO:0000993 9.13 MIR33A MIR145 MIR126

Sources for Arteries, Anomalies of

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....